MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Autor:	Hillengass, Jens 1, Cohen, Adam D 2, Delforge, Michel 3, Einsele, Hermann 4, Goldschmidt, Hartmut 5, Weisel, Katja 6, Raab, Marc-Steffen 7, Scheid, Christof 8, Schecter, Jordan M 9, de Braganca, Kevin C 9, Varsos, Helen 9, Yeh, Tzu-min 9, Mistry, Pankaj 10, Roccia, Tito 10, Corsale, Christina 9, Akram, Muhammad 11, Pacaud, Lida 11, Nesheiwat, Tonia 11, Agha, Mounzer 12, Cohen, Yael C 13
Zdroj:	In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S411-S411
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect